Electrophysiological assessment in patients with long term hypoxia

References

1. ↵
   1. World Health Organization

   (2001) The GOLD global strategy for the management and prevention of COPD (WHO, Geneva (CH)) Available from: http://www.goldcopd.org/uploads/users/files/GOLDWkshp05Clean.pdf. Accessed April 1998; Updated August 2005.
2. ↵
   1. Ahmadi Z,
   2. Bornefalk-Hermansson A,
   3. Franklin AK,
   4. Midgren B,
   5. Ekström MP

   (2014) Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease:a population-based prospective study. Respiratory Research 15, 30.
3. ↵
   1. Katsenos S,
   2. Constantopoulos SH

   (2011) Long-Term Oxygen Therapy in COPD:Factors Affecting and Ways of Improving Patient Compliance. Pulm Med 2011, 325362.
4. ↵
   1. Weinstein GW

   (1978) Clinical aspects of the visually evoked potential. Ophthalmic Surg 9, 56–65.
5. ↵
   1. Nasilowski J,
   2. Przybylowski T,
   3. Zielinski J,
   4. Chazan R

   (2008) Comparing supplementary oxygen benefits from a portable oxygen concentrator and a liquid oxygen portable device during a walk test in COPD patients on long-term oxygen therapy. Respir Med 102, 1021–1025.
6. ↵
   1. Kim KH,
   2. Park TY,
   3. Kim ES,
   4. Chung KB,
   5. Lee SM,
   6. Yim JJ,
   7. et al.

   (2012) Clinical features of patients on home oxygen therapy due to chronic respiratory failure at one university hospital. Korean J Intern Med 27, 311–316.
7. ↵
   1. Tandon OP

   (1998) Average evoked potentials--clinical applications of short latency responses. Indian J Physiol Pharmacol 42, 172–188.
8. ↵
   1. Singh SB,
   2. Thakur L,
   3. Anand JP,
   4. Yadav D,
   5. Amitabh PK,
   6. Banerjee PK,
   7. et al.

   (2004) Changes in visual evoked potentials on acute induction to high altitude. Indian J Med Res 120, 472–477.
9. ↵
   1. Singh B,
   2. Mielke MM,
   3. Parsaik AK,
   4. Cha RH,
   5. Roberts RO,
   6. Scanlon PD,
   7. et al.

   (2014) A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol 71, 581–588.
10. ↵
    1. Kırmemiş O,
    2. Tatlı MM,
    3. Tayman C,
    4. Koca C,
    5. Karadağ A,
    6. Uras N,
    7. et al.

    (2011) Subclinical hypoxia of infants with intrauterine growth retardation determined by increased serum S100B protein levels. Turk J Med Sci 41, 795–800.
11. ↵
    1. Florio P,
    2. Marinoni E,
    3. Di Iorio R,
    4. Bashir M,
    5. Ciotti S,
    6. Sacchi R,
    7. et al.

    (2006) Urinary S100B protein concentrations are increased in intrauterine growth-retarded newborns. Pediatrics 118, 747–754.
12. ↵
    1. Polman CH,
    2. Reingold SC,
    3. Banwell B,
    4. Clanet M,
    5. Cohen JA,
    6. Filippi M,
    7. et al.

    (2011) Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria. Ann Neurol 69, 292–302.
13. ↵
    1. Frischer JM,
    2. Bramow S,
    3. Dal-Bianco A,
    4. Lucchinetti CF,
    5. Rauschka H,
    6. Schmidbauer M,
    7. et al.

    (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175–1189.
14. ↵
    1. Cakmak A,
    2. Soker M,
    3. Koc A,
    4. Erel O

    (2009) Paraoxonase and arylesterase activity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol 31, 583–587.
15. ↵
    1. Aydin O,
    2. Ellidag HY,
    3. Eren E,
    4. Kurtulus F,
    5. Yaman A,
    6. Yılmaz N

    (2014) Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb) 24, 383–389.
16. ↵
    1. Nural S,
    2. Günay E,
    3. Halici B,
    4. Celik S,
    5. Ünlü M

    (2013) Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation 36, 66–74.